Central Centrifugal Cicatricial Alopecia
Conditions
Keywords
hair loss, hair follicle regrowth
Brief summary
The purpose of this pilot study is to determine if calcipotriol shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). This study aims to evaluate calcipotriol due to the possible anti-inflammatory effects that may affect the hair growth cycle.
Detailed description
Calcipotriol, a vitamin D analog, has been topically used to treat alopecia areata, a form of non-scarring autoimmune alopecia in several studies. It is possible that Vitamin D plays a role in sustaining the hair follicle's immune privilege through anti-inflammatory effects such as controlling Interferon gamma (IFN-γ) production. A recent study showed a significant decrease of vitamin D in Black patients with Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
DRUGCalcipotriol
Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
DRUGSubject's already prescribed drug
Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
Sponsors
Wake Forest University Health Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
10 patients for the study will be randomized to one of two groups who consent to participate in a novel treatment with calcipotriol, or the control (no additional treatment besides Subject's already prescribed drug)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women who are eighteen years of age or older * biopsy-proven and/or clinical diagnosis of CCCA Stage II-IV * must be on stable treatment without changes for at least 3 months * Subjects will be recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology.
Exclusion criteria
* Males
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Amount of hairline stabilization | Baseline | Standardized camera and dermatoscopic photographs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Amount of hair regrowth | Baseline, Month 2, Month 4, and Month 6 | Standardized camera and dermatoscopic photographs |
| Signs and symptoms of disease score | Month 2, Month 4, and Month 6 | standardized questionnaire - higher scores denotes worse condition |
| Dermatology Life Quality Index score | Baseline and Month 6 | scores of not at all to very much |
Countries
United States
Outcome results
None listed